PortugalPolitics
Transatlantic Talks: Portugal risks waiting even more for innovative medicines
Publication: ECO
Author: André Veríssimo
Source published: 19/11/2026, 07:01:22 UTC
Briefing created: 19/11/2026, 07:28:12 UTC
Based on a feed excerpt; full article content has not been acquired. Source evidence retrieved 19/11/2026, 07:11:24 UTC.
Briefings
Portuguese pharmaceutical executives from Pfizer and Bial warn that the US 'Most Favored Nation' drug pricing policy may delay access to innovative treatments in Europe. While the US policy lowers prices for American consumers, Portugal is not part of the OECD price reference group, meaning lower prices in the US could indirectly raise costs in other markets, including Portugal. This creates a risk that pharmaceutical companies will hesitate to launch new drugs in Europe due to potential price impacts on their global business.
Key points
- The US 'Most Favored Nation' policy, formalized in May 2025, sets US drug prices at the lowest levels in OECD countries to increase access for American consumers.
- Portugal is not included in the OECD price reference group for the MFN policy, meaning lower US prices do not directly apply to Portugal but may indirectly affect other markets through price transmission mechanisms.
Context
The article discusses how the US administration's policy change affects European pharmaceutical companies. Portugal is currently one of the few countries where access to innovative treatments is delayed, according to executives from Pfizer and Bial. The policy change in May 2025 has created new conditions for drug pricing negotiations between US and European markets.
Limitations
The evidence is limited to interviews with Pfizer and Bial executives discussing the policy impact. The article does not provide specific data on actual price changes, exact delays in drug launches, or quantitative estimates of the economic impact on European pharmaceutical companies.
Generated by Bittrees-hosted qwen35-2b sha256:aaf42c8b7c3c on 19/11/2026, 07:28:12 UTC. Based on publisher-provided feed evidence; may not cover the full original article. Check the source for details.
View archived briefing on IPFS
bafybeidz7hfytvk74ozrcxfplibzzvrjcybmc3udfzdxzlyi37ixjygwfe